<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429337</url>
  </required_header>
  <id_info>
    <org_study_id>CPKC412A2116</org_study_id>
    <secondary_id>2010-020694-16</secondary_id>
    <nct_id>NCT01429337</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function</brief_title>
  <official_title>An Open-label, Multiple Dose, Parallel Group, Phase I Study to Assess the Pharmacokinetics and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this international study is to assess the effect of varying degrees of
      impaired hepatic function compared to a normal hepatic function (Child-Pugh classification)
      on the pharmacokinetics and safety of midostaurin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2011</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite of pharmacokinetics (PK) of midostaurin in subjects with mild, moderate, and severely impaired hepatic function relative to healthy controls by analyzing plasma samples</measure>
    <time_frame>at different timepoints from Day 1 to Day 11</time_frame>
    <description>The following PK parameters for midostaurin and its major metabolites will be assessed at Day 1 and Day 7: For PKC412: tmax, Cmax, AUC(0-τ), t½*, CL/F*, and Vz/F*. For CGP52421: tmax, Cmax, AUC(0-τ), and if applicable t½* For CGP62221: tmax, Cmax, AUC(0-τ), and t½*. *on Day 7 only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the safety and tolerability of midostaurin in subjects with hepatic impairment by assessing the AEs, SAEs, including abnormalities of laboratory parameters</measure>
    <time_frame>During the study and until 28 days follow-up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the relationship between pharmacokinetics and hepatic function parameters by assessing total bilirubin, prothrombin time and albumin</measure>
    <time_frame>At different timepoints from Day 1 to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>potential CYP3A4 induction by midostaurin in the hepatic impaired population by assessing endogenous biomarkers (6beta-hydroxycortisol to cortisol ratio)</measure>
    <time_frame>At different timepoints from Day 3 to Day 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>protein binding by assessing the level of α1-acid glycoprotein (AAG) in plasma samples</measure>
    <time_frame>At baseline (day -1) for the protein binding and Day 1 + Day 7 for the free fraction</time_frame>
    <description>will also determine the free fraction of midostaurin and its metabolites CGP62221 and CGP52421 by assessing the concentration of PKC412 and its metabolites in blood samples.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Normal hepatic function group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Midostaurin 25 mg soft gelatin capsules. The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour-break), from Day 1 to Day 6. On day 7, midostaurine will be administered only in the morning.</description>
    <arm_group_label>Normal hepatic function group</arm_group_label>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_label>Severe hepatic impairment group</arm_group_label>
    <other_name>PKC412</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Subjects must be able to communicate well with the Investigator and comply with the
        requirements of the study.

        Exclusion Criteria:

          -  Significant neurologic or psychiatric disorder which could compromise participation in
             the study.

          -  Subjects with known ongoing alcohol and/or drug abuse within 1 month prior to dosing
             or evidence of such abuse.

          -  Subjects with cotinine levels greater than 500ng/mL are considered as smokers and will
             not be enrolled.

          -  Consumption of alcohol within 3 days prior to dosing or during the study.

          -  Women of childbearing potential unless they are using a highly effective contraception
             method the length of the study and for at least for at least 3 months after the last
             exposure to midostaurin. Highly effective methods include: Total abstinence, female
             sterilization or male partner sterilization. Or use a combination of (a+b): a)
             Placement of an intrauterine device or intrauterine system , b)barrier method of
             contraception

          -  Sexually active males unless they use condom during intercourse while taking
             midostaurin and for at least 3 months after the last exposure to drug. A condom is
             required to be used also by vasectomized men.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj</city>
        <state>Napoca</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hepatic impaired patients</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Varying degrees of hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midostaurin</mesh_term>
    <mesh_term>Staurosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

